Novo hopes slimmed-down bet can still win in obesity
Tag: Saxenda
Novo Nordisk U.S. Sales Slump in 2Q and Predicts Continued Decline for 2019
Shares of Danish drugmaker Novo Nordisk are down about five percent this morning after the company reported an overall decline in sales during the second quarter of this year. Sales were particularly disappointing in North America, which saw a 10 percent drop, the company said. Novo reported that for 2019 sales in the United States could face some struggles … Continue reading Novo Nordisk U.S. Sales Slump in 2Q and Predicts Continued Decline for 2019
Eisai’s Obesity Drug Belviq Passes Cardiovascular Outcomes Test
Eisai Co. Ltd./Arena Pharmaceuticals Inc.'s obesity drug Belviq (lorcaserin HCI) has proven that it doesn't pose cardiovascular risks in the CAMELLIA-TIMI 61 cardiovascular outcomes study, but it hasn't shown a benefit for reducing major events and it remains to be seen whether the new data will have any commercial effect on small sales. Patients taking Belviq … Continue reading Eisai’s Obesity Drug Belviq Passes Cardiovascular Outcomes Test
Intelligence Pharma 
You must be logged in to post a comment.